Author Archives: Scalper1

Comcast, Maybe Apple, Aim To Get Skinny TV Right

When Comcast launches a Web-based TV service this fall, first in Boston, it’ll be an acid test for another spin of the “skinny bundle” — a lower-priced TV package with limited channels. Apple (AAPL) will pay attention, analysts say, because its much-anticipated Web-TV service may resemble Comcast’s in some ways, if as expected it’s launched in 2016. The launch depends on whether Apple can negotiate streaming rights to live broadcast content, as

Time Your Buys Like A Pro

By Jonathan Rodriguez For traditional buy-and-hold investors, market timing probably doesn’t mean much. But here’s the thing: It should. Believe it or not, many smart people are investing the wrong way every single day. These investors see a stock on the rise and chase shares when everyone else is buying – and that means they’re often buying too high. And then, when the market sells off, they dump shares along with everyone else – often at too low a price. Professional traders know this and mint fortunes off the herd. But by using one simple indicator, you can time your entries alongside the elite traders. Once you’ve identified a quality stock, the first step is to buy shares at the lowest price you can. You see, stocks never go up or down in a straight line. When a stock trends upward, it ascends the chart in waves. Shares rally under momentum and fall on profit taking. In order to buy the dips and sell the rallies, I use one of my favorite technical indicators: Bollinger Bands. Developed by John Bollinger in the 1980s, Bollinger Bands are volatility bands placed above and below a stock’s moving average. The bands’ values are based on standard deviations from the moving average. You can select any moving average and deviation, but traders typically use the 20-day moving average (DMA) and set the Bollinger Bands at two standard deviations above and below the DMA. I love Bollinger Bands because they combine several technical tools into an easy-to-use trend indicator. And because the bands utilize standard deviations, they adjust automatically for rapid changes in volatility. Once the bands are set, price action bounces between the upper and lower band as momentum swings. The idea is to buy shares as they “tag” the lower band and sell as they tag the upper band. Let’s look at an applied example. Here’s a one-year chart of Under Armour Inc. (NYSE: UA ), one of 2015’s hottest stocks. Over the last year, shares have outperformed the S&P 500 by more than 60%. As you can see, price action is contained between the Bollinger Bands. And by timing your entry on a dip to the lower band, you can increase your profits by several percentage points. On the chart, you’ll notice three distinct buy signals: December 2014-January 2015, May-June 2015, and August 2015. After executing a buy, you can sell on the upper band tag or hold until you’ve hit your profit target. Now, on a pricier large-cap stock, a few percentage points in profit might not mean much. But if you’re an options trader or short-term trader, those points can be the difference between small gains and big money. And the bands become even more valuable when trading volatile small-cap and mid-cap stocks. Bottom line: Don’t chase red-hot stocks at recent highs. Use Bollinger Bands to time the dips and get more bang for your buck. Original Post

The First Cancer Immunotherapy ETF

Investors can target immunotherapy cancer treatment companies through a new ETF. A look at the Loncar Cancer Immunotherapy ETF. Provides exposure to a quickly growing segment of the biotechnology space. With the advancements in biotechnology generating some attractive investment opportunities, exchange traded fund investors may now focus on a group of companies that specialize in the growing field of cancer immunotherapy. The Loncar Cancer Immunotherapy ETF (NasdaqGM: CNCR ) began trading Wednesday, October 14, according to a press release . CNCR has a 0.79% expense ratio. “Immunotherapy is changing the way many cancers are being treated,” Brad Loncar, Chief Executive Officer of Loncar Investments, said in the press release. “This innovative field within biotechnology is expected to become the foundational treatment for cancer over the next ten years. We think it is important to give investors a benchmark to track the progress of this growing biotechnology sector, which over time will likely continue to have a positive impact on society.” CNCR tries to reflect the performance of the Loncar Cancer Immunotherapy Index, which was developed by biotechnology investor Brad Loncar. The underlying index tracks large pharmaceutical and growth-oriented biotechnology companies in the cancer treatment space. Specifically, the index tracks companies that are developing new classes of therapies, like checkpoint inhibitors, next generation vaccines and chimeric antigen receptor (CAR) technologies. “Biotech stocks tend to get grouped together as a whole, yet areas like immunotherapy trade on their own unique circumstances and innovations,” according to Loncar Investments. “While traditional medicines like chemotherapies often give cancer a broad punch, the benefit of using immunotherapy is derived from the immune system’s dynamic nature and the way it can more precisely be tailored to fight a patient’s disease.” The underlying index first selects seven top large pharmaceutical companies working on immunotherapy for their strategic focus on cancer treatment and their leadership role in the field. Additionally, the index picks the top 23 growth biotechnology companies in immunotherapy by market capitalization. The cancer index is then equally weighted. The index also screens companies for a number of factors, including drugs approved by either the FDA or EMA that harness the immune system to fight cancer, drugs in the human stage of testing that harnesses the immune system, intentions to begin human stage testing of a drug that harnesses the immune system to fight cancer, or announcement of an immunotherapy collaboration or partnership with a major pharmaceutical company. Top holdings include Ziopharm Oncology (NASDAQGS: ZIOP ) 4.9%, Kite Pharma (NASDAQGS: KITE ) 4.7%, Celgene (NASDAQGS: CELG ) 4.7%, Pfizer (NASDAQGS: PFE ) 4.5% and Bristol-Myers (NASDAQGS: BMY ) 4.4%. “The Loncar Cancer Immunotherapy ETF allows investors to participate in the breakthrough in this well-defined sector in a diversified way,” J. Garrett Stevens, CEO of Exchange Traded Concepts, said in the press release. A cancer-themed ETF is not new to the ETF industry. Previously, ETF investors could tap into this segment of the biotech industry through the HealthShares Cancer ETF ( HHK ), but the fund closed in 2008. Additionally, XShares, the fund provider of the HealthShares line, was sold to a unit of Deutsche Bank in 2010. Max Chen contributed to this article . Disclosure: None.